|Compound||Class of Compound||Phase of Development||Pharmaceutical Company|
|ACH-126,443 (L-Fd4C)||Nucleoside analogue RT inhibitor||Phase I||Achilleon|
|ADA||Zinc finger||Phase I/II||Hubriphar|
|BMS-232623||Protease inhibitor||Phase II/III||Bristol-Myers Squibb (BMS)|
|Calanolide A||Non-nucleoside RT inhibitor||Phase II||Sarawak Medichem|
|Capravirine||Non-nucleoside RT inhibitor||Phase II||Agouron|
|DAPD||Nucleoside analogue RT inhibitor||Phase I/II||Triangle Pharmaceuticals|
|DEHSPM||Inhibits hypusin/eIF-5A||Phase I||SunPharm|
|DPC 083||Non-nucleoside RT inhibitor||Phase I||(BMS) DuPont Pharmaceuticals|
|DPC 961||Non-nucleoside RT inhibitor||Phase I||(BMS) DuPont Pharmaceuticals|
|Emivirine (MKC-442)||Non-nucleoside RT inhibitor||Phase III||Triangle Pharmaceuticals|
|Emtricitabine (FTC)||Nucleoside analogue RT inhibitor||Phase III||Triangle Pharmaceuticals|
|Hydroxyurea||Inhibits cellular factors||Phase II/III||Bristol-Myers Squibb|
|Mycophenlate||Inhibits cellular factors||Phase I/II||Hoffman-La Roche|
|Peldesine||Inhibits cellular factors||Phase I||Biocryst|
|Pentfuside (T-20)||Fusion inhibitor||Phase III||Trimeris/Roche|
|PRO 367||Entry inhibitor||Phase I||Progenics|
|PRO 542||Attachment inhibitor||Phase I/II||Progenics|
|Resveratrol||Inhibits cellular factors||Phase I||Pharmascience|
|S1360||Integrase inhibitor||Phase I/II||Shionogi Pharmaceuticals|
|SCH C||CCR5 antagonist||Phase I||Schering Plough|
|T-1249||Fusion inhibitor||Phase I||Trimeris/Roche|
|Tipranavir||Protease inhibitor||Phase I/II||Boehringer Ingelheim|
|TMC 125||Non-nucleoside RT inhibitor||Phase II||Tibotec|
|TMC 120||Non-nucleoside RT inhibitor||Phase II||Tibotec|
|TMC 126||Protease inhibitor||Phase I||Tibotec|
|VX-175/GW433908 Vertex/Glaxo||Protease inhibitor||Phase II/III||SmithKline (amprenavir prodrug)|
|* Source: Ben Cheng, Project Inform. Visit www.atac-usa.org.|
Phase I trials involve the first introduction of an experimental drug to patients or healthy volunteers, normally less than 100 enrollees. They are closely monitored to determine the interaction of the drug, including the side effects associated with different doses. Sufficient information and signs of effectiveness are necessary to permit design of well-controlled Phase II studies.
Phase II trials are well controlled, closely monitored clinical studies, usually with no more than several hundred human subjects. They test the effectiveness of a drug against a particular indication(s) in patients with the disease or condition in question and measure common, short-term side effects and risks associated with the drug.
Phase III trials are expanded controlled and uncontrolled studies, including several hundred to several thousand participants, initiated after preliminary data of drug effectiveness are obtained. These trials seek to gather additional effectiveness and safety information about safety and evaluate the overall benefit-risk relationship of the drug and to provide competent basis for dosing.
Adapted from the HIV/AIDS Treatment Information Service (www.hivatis.org).